Zhejiang Yatai Pharmaceutical Co Ltd (002370) - Net Assets
Based on the latest financial reports, Zhejiang Yatai Pharmaceutical Co Ltd (002370) has net assets worth CN¥1.12 Billion CNY (≈ $163.55 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.23 Billion ≈ $180.41 Million USD) and total liabilities (CN¥115.18 Million ≈ $16.86 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how large is Zhejiang Yatai Pharmaceutical Co Ltd's balance sheet for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.12 Billion |
| % of Total Assets | 90.66% |
| Annual Growth Rate | 11.37% |
| 5-Year Change | 158.75% |
| 10-Year Change | -48.29% |
| Growth Volatility | 66.68 |
Zhejiang Yatai Pharmaceutical Co Ltd - Net Assets Trend (2006–2025)
This chart illustrates how Zhejiang Yatai Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Check 002370 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Zhejiang Yatai Pharmaceutical Co Ltd (2006–2025)
The table below shows the annual net assets of Zhejiang Yatai Pharmaceutical Co Ltd from 2006 to 2025. For live valuation and market cap data, see market cap of Zhejiang Yatai Pharmaceutical Co Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.12 Billion ≈ $163.93 Million |
+15.23% |
| 2024-12-31 | CN¥972.18 Million ≈ $142.26 Million |
+67.37% |
| 2023-12-31 | CN¥580.87 Million ≈ $85.00 Million |
+92.84% |
| 2022-12-31 | CN¥301.22 Million ≈ $44.08 Million |
-30.43% |
| 2021-12-31 | CN¥432.96 Million ≈ $63.36 Million |
-34.44% |
| 2020-12-31 | CN¥660.41 Million ≈ $96.64 Million |
+4.32% |
| 2019-12-31 | CN¥633.06 Million ≈ $92.64 Million |
-73.36% |
| 2018-12-31 | CN¥2.38 Billion ≈ $347.71 Million |
+4.30% |
| 2017-12-31 | CN¥2.28 Billion ≈ $333.36 Million |
+5.15% |
| 2016-12-31 | CN¥2.17 Billion ≈ $317.02 Million |
+173.14% |
| 2015-12-31 | CN¥793.15 Million ≈ $116.06 Million |
+6.13% |
| 2014-12-31 | CN¥747.31 Million ≈ $109.36 Million |
+5.28% |
| 2013-12-31 | CN¥709.83 Million ≈ $103.87 Million |
+0.84% |
| 2012-12-31 | CN¥703.94 Million ≈ $103.01 Million |
-5.55% |
| 2011-12-31 | CN¥745.30 Million ≈ $109.06 Million |
+3.52% |
| 2010-12-31 | CN¥719.95 Million ≈ $105.35 Million |
+213.31% |
| 2009-12-31 | CN¥229.79 Million ≈ $33.63 Million |
+15.65% |
| 2008-12-31 | CN¥198.69 Million ≈ $29.07 Million |
+25.81% |
| 2007-12-31 | CN¥157.93 Million ≈ $23.11 Million |
+9.08% |
| 2006-12-31 | CN¥144.78 Million ≈ $21.19 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Yatai Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2874.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥2.81 Billion | 250.94% |
| Total Equity | CN¥1.12 Billion | 100.00% |
Zhejiang Yatai Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Yatai Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vaalco Energy Inc
NYSE:EGY
|
$551.11 Million |
|
Sharda Motor Industries Limited
NSE:SHARDAMOTR
|
$551.28 Million |
|
MapLight Therapeutics, Inc. Common Stock
NASDAQ:MPLT
|
$551.37 Million |
|
Beijing Jiaxun Feihong Electrical Co Ltd
SHE:300213
|
$551.42 Million |
|
Huamei Holding
SHE:000607
|
$551.01 Million |
|
Guangzhou Grandbuy Co Ltd
SHE:002187
|
$550.76 Million |
|
Laurent-Perrier
PA:LPE
|
$550.73 Million |
|
Tekla Life Sciences Investors
NYSE:HQL
|
$550.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Yatai Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 972,181,003 to 1,120,286,883, a change of 148,105,880 (15.2%).
- Net income of 96,307,828 contributed positively to equity growth.
- Dividend payments of 37,371,378 reduced retained earnings.
- Other comprehensive income decreased equity by 132,521,363.
- Other factors increased equity by 221,690,794.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥96.31 Million | +8.6% |
| Dividends Paid | CN¥37.37 Million | -3.34% |
| Other Comprehensive Income | CN¥-132.52 Million | -11.83% |
| Other Changes | CN¥221.69 Million | +19.79% |
| Total Change | CN¥- | 15.23% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Yatai Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.36x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 11.06x to 3.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.46 | CN¥5.05 | x |
| 2007-12-31 | CN¥0.51 | CN¥5.05 | x |
| 2008-12-31 | CN¥0.65 | CN¥5.05 | x |
| 2009-12-31 | CN¥0.76 | CN¥5.05 | x |
| 2010-12-31 | CN¥1.88 | CN¥5.05 | x |
| 2011-12-31 | CN¥1.79 | CN¥5.05 | x |
| 2012-12-31 | CN¥1.78 | CN¥5.05 | x |
| 2013-12-31 | CN¥1.94 | CN¥5.05 | x |
| 2014-12-31 | CN¥1.84 | CN¥5.05 | x |
| 2015-12-31 | CN¥1.91 | CN¥5.05 | x |
| 2016-12-31 | CN¥4.82 | CN¥5.05 | x |
| 2017-12-31 | CN¥4.26 | CN¥5.05 | x |
| 2018-12-31 | CN¥4.44 | CN¥5.05 | x |
| 2019-12-31 | CN¥1.18 | CN¥5.05 | x |
| 2020-12-31 | CN¥1.21 | CN¥5.05 | x |
| 2021-12-31 | CN¥0.82 | CN¥5.05 | x |
| 2022-12-31 | CN¥0.57 | CN¥5.05 | x |
| 2023-12-31 | CN¥0.98 | CN¥5.05 | x |
| 2024-12-31 | CN¥1.42 | CN¥5.05 | x |
| 2025-12-31 | CN¥1.50 | CN¥5.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Yatai Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.60%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 29.80%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.14x
- Recent ROE (8.60%) is above the historical average (-12.95%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 15.46% | 7.78% | 0.86x | 2.32x | CN¥7.58 Million |
| 2007 | 24.75% | 11.41% | 0.95x | 2.29x | CN¥23.29 Million |
| 2008 | 20.94% | 10.02% | 1.01x | 2.06x | CN¥21.74 Million |
| 2009 | 20.95% | 11.21% | 0.97x | 1.92x | CN¥25.17 Million |
| 2010 | 5.84% | 9.66% | 0.50x | 1.20x | CN¥-29.95 Million |
| 2011 | 5.88% | 10.42% | 0.48x | 1.17x | CN¥-30.74 Million |
| 2012 | -3.65% | -8.14% | 0.39x | 1.16x | CN¥-96.11 Million |
| 2013 | 0.77% | 1.75% | 0.39x | 1.13x | CN¥-65.50 Million |
| 2014 | 5.43% | 10.80% | 0.44x | 1.14x | CN¥-34.16 Million |
| 2015 | 7.06% | 11.98% | 0.22x | 2.62x | CN¥-23.08 Million |
| 2016 | 5.81% | 14.52% | 0.35x | 1.13x | CN¥-90.42 Million |
| 2017 | 8.91% | 18.67% | 0.38x | 1.26x | CN¥-24.64 Million |
| 2018 | 8.79% | 15.87% | 0.37x | 1.50x | CN¥-28.65 Million |
| 2019 | -303.40% | -271.29% | 0.31x | 3.58x | CN¥-1.98 Billion |
| 2020 | 4.13% | 5.30% | 0.26x | 2.96x | CN¥-38.77 Million |
| 2021 | -52.73% | -72.44% | 0.20x | 3.72x | CN¥-271.58 Million |
| 2022 | -44.05% | -35.53% | 0.25x | 5.06x | CN¥-162.81 Million |
| 2023 | -2.04% | -2.82% | 0.29x | 2.46x | CN¥-69.96 Million |
| 2024 | 3.52% | 8.45% | 0.29x | 1.44x | CN¥-62.98 Million |
| 2025 | 8.60% | 29.80% | 0.25x | 1.14x | CN¥-15.72 Million |
Industry Comparison
This section compares Zhejiang Yatai Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,756,487,677
- Average return on equity (ROE) among peers: 1.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Yatai Pharmaceutical Co Ltd (002370) | CN¥1.12 Billion | 15.46% | 0.10x | $551.03 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $642.98 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $536.15 Million | 4.62% | 0.32x | $376.71 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $793.34 Million | 10.94% | 0.24x | $5.15 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $546.67 Million | 0.00% | 0.46x | $2.65 Billion |
| Wedge Industrial Co Ltd (000534) | $1.55 Billion | 12.44% | 1.56x | $1.93 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $38.34 Billion | 14.39% | 0.44x | $13.50 Billion |
| Hainan Haiyao Co Ltd (000566) | $384.18 Million | -22.43% | 1.41x | $1.11 Billion |
| Tus Pharmaceutical Group Co Ltd (000590) | $231.22 Million | -38.13% | 1.23x | $303.82 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $869.73 Million | 4.99% | 1.99x | $977.31 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $2.34 Billion | 20.86% | 0.40x | $3.20 Billion |
About Zhejiang Yatai Pharmaceutical Co Ltd
Zhejiang Yatai Pharmaceutical Co., Ltd. researches, produces, sells, and exports pharmaceutical products in China and internationally. The company offers solid dosage, cephalosporin powder injection, and freeze-dried powder injection products. It also provides various antibiotic and non-antibiotic drugs. The company was founded in 1989 and is based in Shaoxing, China.